Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (361-370 of 398) with videos related to

Pageof 40
Sort By:
EJNMMI Research|July 27, 2019
Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancerCristina Müller, Aviral Singh, Christoph A Umbricht, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2026
Antitumor efficacy and safety of locoregional [<sup>177</sup>Lu]Lu-RM26 radionuclide therapy in glioblastomaLi'ao Wang, Jialin Xiang, Linlin Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 2026
Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>225</sup>Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced MalignanciesRichard P Baum, Tianzhi Zhao, Vivianne Jakobsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans ResultsRichard P Baum, Christiane Schuchardt, Aviral Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2018
PRRT genomic signature in blood for prediction of <sup>177</sup>Lu-octreotate efficacyLisa Bodei, Mark S Kidd, Aviral Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 16, 2019
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETestLisa Bodei, Mark S Kidd, Aviral Singh, et al.
Cancers|November 24, 2020
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive MicroenvironmentAntonia Busse, Liliana H Mochmann, Christiane Spenke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2018
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward Wolin, Beth Chasen, et al.
Annals of Surgery|December 16, 2024
Trends in the Management and Outcomes of Neuroendocrine Liver Metastases: A Three-decade, Multi-centre Observational Cohort StudyAndrea Frilling, Ashley K Clift, Daniel Kaemmerer, et al.
Pageof 40

Showing results (361-370 of 398) with videos related to

Sort By:
Pageof 40
EJNMMI Research|July 27, 2019
Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancerCristina Müller, Aviral Singh, Christoph A Umbricht, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2026
Antitumor efficacy and safety of locoregional [<sup>177</sup>Lu]Lu-RM26 radionuclide therapy in glioblastomaLi'ao Wang, Jialin Xiang, Linlin Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 2026
Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>225</sup>Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced MalignanciesRichard P Baum, Tianzhi Zhao, Vivianne Jakobsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans ResultsRichard P Baum, Christiane Schuchardt, Aviral Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2018
PRRT genomic signature in blood for prediction of <sup>177</sup>Lu-octreotate efficacyLisa Bodei, Mark S Kidd, Aviral Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 16, 2019
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETestLisa Bodei, Mark S Kidd, Aviral Singh, et al.
Cancers|November 24, 2020
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive MicroenvironmentAntonia Busse, Liliana H Mochmann, Christiane Spenke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2018
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward Wolin, Beth Chasen, et al.
Annals of Surgery|December 16, 2024
Trends in the Management and Outcomes of Neuroendocrine Liver Metastases: A Three-decade, Multi-centre Observational Cohort StudyAndrea Frilling, Ashley K Clift, Daniel Kaemmerer, et al.
Pageof 40